Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Vigezo vya Utambuzi vya Rome IV kwa Ugonjwa wa Utumbo unaowashwawashwa× | Kifupi cha Dodoso la Magonjwa ya Kuvimba Utumbo× | |
|---|---|---|
| Nyanja | Gastroenterolojia | Gastroenterolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 2016 | 2004 |
| Mwanzilishi≠ | Rome Foundation (multinational expert consensus) | Guyonnet, D., Chassany, O., Ducroc, R., et al. |
| Aina≠ | Diagnostic Criteria | Self-report |
| Chanzo asilia≠ | Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation. link ↗ | Guyonnet, D., Chassany, O., Ducroc, R., Picard, C., Mouret, M., D'Haens, G., & Svartz, H. (2004). Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in France: A multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 20(4), 459–465. link ↗ |
| Majina mbadala | Rome IV IBS, Rome Criteria | IBDQ-32, Short IBDQ |
| Zinazohusiana | 4 | 4 |
| Muhtasari≠ | The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns. | The Short Inflammatory Bowel Disease Questionnaire (IBDQ-32) is a validated patient-reported outcome measure designed to assess the impact of inflammatory bowel disease (IBD)—both ulcerative colitis and Crohn's disease—on health-related quality of life. Derived from the original 32-item IBDQ, this instrument comprises four domains: Bowel Symptoms, Systemic Symptoms, Social Function, and Emotional Function. The IBDQ-32 is responsive to treatment and is increasingly used in IBD clinical trials and practice. |
| ScholarGateSeti ya data ↗ |
|
|